STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1281 by analyst upside · 2026-08-13
KRRO
Korro Bio, Inc.
Healthcare · Market Cap $197M · P/E 0x
ANALYST PRICE TARGET
+51.3%
implied upside to consensus target
Current Price $13.35
Consensus Target $20.2
Bull Target $30.0
Bear Target $10.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
7
Hold
1
Sell
0
52-Week Low $5.2
52-Week High $55.89
YTD Return +65.8%
FUNDAMENTALS
Market Cap $197M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-9.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $5.2
52-Week High $55.89
Current Price $13.35
Bear Target $10.0
Bull Target $30.0
● Now $13.35 ● Target $20.2
TRADING DATA
Avg Volume 196K
YTD Return +65.8%
Analyst Count 10
Consensus Buy
Upside to Target +51.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Korro Bio, Inc. (KRRO) is currently trading at $13.35 with a Wall Street consensus price target of $20.2, implying potential upside of 51.3% over the next 12 months. 10 analysts currently cover KRRO, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $10.0.

KRRO operates in the Healthcare sector with a market capitalisation of $197M. The stock is up 65.8% year-to-date and is currently trading near the lower end of its 52-week range of $5.2 – $55.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KRRO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-19 31% win rate (48 calls)
Citigroup ● Initiated
Buy 2026-05-18 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-03-13 40% win rate (10 calls)
Raymond James ↑ Upgrade
Market Perform → Outperform 2026-03-13 Building track record
Clear Street ↑ Upgrade
Hold → Buy 2026-02-19 Building track record
William Blair ↑ Upgrade
Market Perform → Outperform 2026-02-17 44% win rate (9 calls)
Chardan Capital ↑ Upgrade
Neutral → Buy 2026-01-29 33% win rate (6 calls)
HC Wainwright & Co. ↑ Upgrade
Neutral → Buy 2026-01-29 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →